Coronavirus Update: Lukewarm US Panel For Molnupiravir, Inovio, Bharat Look At Omicron
Plus, J&J Nears S African Deal, Serum Exports Novavax Vaccine, Ocugen Trial On Hold
Executive Summary
A US FDA review panel has given a lukewarm reception to molnupiravir, while Inovio is assessing its vaccine candidates against the new omicron variant, J&J nears a South African vaccine deal with Aspen, and South Korea brings in new COVID-19 measures. Meanwhile, Serum exports Novavax vaccine, Bharat looks at Covaxin in Omicron and Ocugen's Covaxin trial put on hold.
You may also be interested in...
Aspen Explains U-Turn On Withdrawing From Proposed API Sale
Following years of reshaping its operations, one part of Aspen Pharmacare’s business that is to stay for now is the firm’s API division. The South African firm’s management explained why as Aspen presented results from its financial first half, hours after wrapping up a key COVID-19 licensing deal with Johnson & Johnson.
Coronavirus Notebook: Vaccine Approvals In India Amid Wins And Losses For Drug Developers In China
India has issued emergency approvals for a number of new COVID-19 vaccines and extended eligible age groups for others, while developers of potential drug therapies in China have seen both gains and setbacks.
Coronavirus Update: India Approves Multiple New Vaccines
India has issued emergency approvals for a number of new vaccines and extended eligible age groups for others, while developers of potential drug therapies in China see both gains and setbacks.